Michael R. Martin's most recent trade in PROG Holdings Inc was a trade of 5,592 Common Stock done at an average price of $26.8 . Disclosure was reported to the exchange on May 7, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| PROG Holdings Inc | Ramon Michael Martinez | Director | Grant, award, or other acquisition of securities at price $ 26.82 per share. | 07 May 2025 | 5,592 | 22,292 (0%) | 0% | 26.8 | 149,977 | Common Stock |
| PROG Holdings Inc | Ramon Michael Martinez | Director | Grant, award, or other acquisition of securities at price $ 36.13 per share. | 15 May 2024 | 4,151 | 16,536 (0%) | 0% | 36.1 | 149,976 | Common Stock |
| PROG Holdings Inc | Ramon Michael Martinez | Director | Grant, award, or other acquisition of securities at price $ 32.22 per share. | 24 May 2023 | 4,656 | 12,358 (0%) | 0% | 32.2 | 150,016 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 107,202 | 259,162 (0%) | 0% | - | Common Stock | |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Purchase of securities on an exchange or from another person at price $ 5.16 per share. | 07 Nov 2022 | 30,000 | 89,512 (0%) | 0% | 5.2 | 154,800 | Common Stock |
| PROG Holdings Inc | Ramon Michael Martinez | Director | Grant, award, or other acquisition of securities at price $ 24.99 per share. | 24 May 2022 | 5,002 | 7,702 (0%) | 0% | 25.0 | 125,000 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 106,838 | 106,838 | - | - | Stock Option (right to buy) | |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 62,448 | 62,448 | - | - | Restricted Stock Unit | |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2022 | 8,500 | 64,361 (0%) | 0% | 0 | Common Stock | |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 02 Mar 2022 | 4,849 | 59,512 (0%) | 0% | 12.0 | 58,236 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 31.26 per share. | 09 Nov 2021 | 50,000 | 76,861 (0%) | 0% | 31.3 | 1,563,000 | Common Shares |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 30.17 per share. | 09 Nov 2021 | 50,000 | 126,861 (0%) | 0% | 30.2 | 1,508,500 | Common Shares |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 28.82 per share. | 09 Nov 2021 | 29,000 | 66,861 (0%) | 0% | 28.8 | 835,780 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.38 per share. | 09 Nov 2021 | 29,000 | 95,861 (0%) | 0% | 18.4 | 533,020 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Nov 2021 | 29,000 | 27,900 | - | - | Stock Option (right to buy) | |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 29.50 per share. | 09 Nov 2021 | 11,000 | 55,861 (0%) | 0% | 29.5 | 324,500 | Common Shares |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 30.55 per share. | 09 Nov 2021 | 10,000 | 66,861 (0%) | 0% | 30.6 | 305,500 | Common Shares |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 31.64 per share. | 01 Nov 2021 | 45,000 | 176,861 (0%) | 0% | 31.6 | 1,423,800 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2021 | 45,000 | 0 | - | - | Stock Option (right to buy) | |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.20 per share. | 01 Nov 2021 | 45,000 | 221,861 (0%) | 0% | 3.2 | 144,000 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 24.02 per share. | 20 Sep 2021 | 87,500 | 176,861 (0%) | 0% | 24.0 | 2,101,750 | Common Shares |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2021 | 70,000 | 0 | - | - | Option Grant (right to buy) | |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.06 per share. | 20 Sep 2021 | 70,000 | 254,361 (0%) | 0% | 6.1 | 424,200 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2021 | 28,500 | 7,500 | - | - | Option Grant (right to buy) | |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.30 per share. | 20 Sep 2021 | 28,500 | 205,361 (0%) | 0% | 5.3 | 151,050 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 21.60 per share. | 20 Sep 2021 | 16,000 | 176,861 (0%) | 0% | 21.6 | 345,600 | Common Shares |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 21.71 per share. | 20 Sep 2021 | 12,500 | 192,861 (0%) | 0% | 21.7 | 271,375 | Common Shares |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2021 | 10,000 | 56,900 | - | - | Option Grant (right to buy) | |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 18.38 per share. | 20 Sep 2021 | 10,000 | 264,361 (0%) | 0% | 18.4 | 183,800 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Sep 2021 | 7,500 | 0 | - | - | Option Grant (right to buy) | |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.30 per share. | 20 Sep 2021 | 7,500 | 184,361 (0%) | 0% | 5.3 | 39,750 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.30 per share. | 14 Sep 2021 | 44,000 | 220,861 (0%) | 0% | 5.3 | 233,200 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Sep 2021 | 44,000 | 36,000 | - | - | Option Grant (right to buy) | |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 21.80 per share. | 14 Sep 2021 | 30,000 | 176,861 (0%) | 0% | 21.8 | 654,000 | Common Shares |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 21.73 per share. | 14 Sep 2021 | 14,000 | 206,861 (0%) | 0% | 21.7 | 304,220 | Common Shares |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 21.19 per share. | 10 Sep 2021 | 90,000 | 176,861 (0%) | 0% | 21.2 | 1,907,217 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.20 per share. | 10 Sep 2021 | 45,000 | 266,861 (0%) | 0% | 3.2 | 144,000 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.30 per share. | 10 Sep 2021 | 45,000 | 221,861 (0%) | 0% | 5.3 | 238,500 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2021 | 45,000 | 45,000 | - | - | Option Grant (right to buy) | |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2021 | 45,000 | 80,000 | - | - | Option Grant (right to buy) | |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2021 | 25,000 | 125,000 | - | - | Option Grant (right to buy) | |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 19.80 per share. | 10 Sep 2021 | 25,000 | 176,861 (0%) | 0% | 19.8 | 495,000 | Common Shares |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.30 per share. | 10 Sep 2021 | 25,000 | 201,861 (0%) | 0% | 5.3 | 132,500 | Common Shares |
| PROG Holdings Inc | Ramon Michael Martinez | Director | Grant, award, or other acquisition of securities at price $ 46.29 per share. | 09 Sep 2021 | 2,700 | 2,700 (0%) | 0% | 46.3 | 124,983 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 18.10 per share. | 07 Sep 2021 | 7,500 | 176,861 (0%) | 0% | 18.1 | 135,750 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 17.81 per share. | 26 Aug 2021 | 22,500 | 184,361 (0%) | 0% | 17.8 | 400,725 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 16.01 per share. | 09 Aug 2021 | 5,000 | 206,861 (0%) | 0% | 16.0 | 80,050 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 13.86 per share. | 28 Jul 2021 | 5,000 | 211,861 (0%) | 0% | 13.9 | 69,300 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Sale of securities on an exchange or to another person at price $ 13.76 per share. | 22 Jun 2021 | 5,000 | 216,861 (0%) | 0% | 13.8 | 68,800 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.02 per share. | 11 May 2021 | 20,000 | 221,861 (0%) | 0% | 3.0 | 60,400 | Common Stock |
| Aurinia Pharma Inc | Michael R. Martin | Chief Business Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 May 2021 | 20,000 | 0 | - | - | Option Grant (right to buy) |